Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease

References

• . Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131(9):688–695
   Google Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW. Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . Vazquez E, Sanchez—Perales C, Garcia—Garcia F, . Atrial fibrillation in incident dialysis patients. Kidney Int. 2009;76(3):324–330
   PubMed Web of Science ®Google Scholar
• . Genovesi S, Pogliani D, Faini A, . Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005;46(5):897–902
   PubMed Web of Science ®Google Scholar
• . Olesen J, Lip GY, Kamper A, . Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–635
   PubMed Web of Science ®Google Scholar
• . Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(1):105–110
   PubMed Web of Science ®Google Scholar
• . Hobbs FD, Fitzmaurice DA, Mant J, . A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9(40):iii–iv, ix-x, 1–74
   PubMed Web of Science ®Google Scholar
• . Lloyd—Jones DM, Wang TJ, Leip EP, . Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046
   PubMed Web of Science ®Google Scholar
• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Huxley RR, Lopez FL, Folsom AR, . Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(14):1501–1508
   PubMed Web of Science ®Google Scholar
• . Schnabel RB, Sullivan LM, Levy D, . Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739–745
   PubMed Web of Science ®Google Scholar
• . Chamberlain AM, Agarwal SK, Folsom AR, . A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107(1):85–91
   PubMed Web of Science ®Google Scholar
• . Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol. 2012;8(10):569–578
   PubMed Web of Science ®Google Scholar
• . Korantzopoulos P, Kokkoris S, Liu T, Protopsaltis I, Li G, Goudevenos JA. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol. 2007;30(11):1391–1397
   Google Scholar
• . Wetmore JB, Mahnken JD, Rigler SK, . The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012;81(5):469–476
   Google Scholar
• . Wizemann VTong L, Satayathum S, . Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77(12):1098–1106
   PubMed Web of Science ®Google Scholar
• . Ozcan T, Horoz M, Genctoy G, Uyar B, Camsari A, Kiykim AA. The influence of hemodialysis on P-wave signal-averaged electrocardiogram findings. Artif Organs. 2007;31(8):612–616
   Google Scholar
• . Szabo Z, Kakuk G, Fulop T, . Effects of haemodialysis on maximum P wave duration and P wave dispersion. Nephrol Dial Transplant. 2002;17(9):1634–1638
   Google Scholar
• . McManus DD, Corteville DCM, Shlipak MG, Whooley MA, Ix JH. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104(11):1551–1555
   PubMed Web of Science ®Google Scholar
• . Sandhu RK, Kurth T, Conen D, Cook NRRidker PM, Albert CM. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol. 2012;109(4):538–542
   Google Scholar
• . Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629–636
   PubMed Web of Science ®Google Scholar
• . Healey JS, Connolly SJ, Gold MR, ; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129
   PubMed Web of Science ®Google Scholar
• . Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159(4):665–671
   Google Scholar
• . Nishimura M, Hashimoto T, Kobayashi H, . The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant. 2003;18(11):2339–2347
   Google Scholar
• . Genovesi S, Vincenti A, Rossi E, . Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008;51(2):255–262
   PubMed Web of Science ®Google Scholar
• . Toyoda K, Fujii K, Fujimi S, . Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis. 2005;45(6):1058–1066
   PubMed Web of Science ®Google Scholar
• . Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21(1):35–39
   Google Scholar
• . Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman—Breen CO. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol. 2003;14(10):2623–2631
   Google Scholar
• . Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman—Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603–609
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Connolly SJ, Gao P, . Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429–435
   Google Scholar
• . Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599–2604
   PubMed Web of Science ®Google Scholar
• . Nakagawa K, Hirai T, Takashima S, . Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107(6):912–916
   Google Scholar
• . Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19(4):317–322
   PubMedGoogle Scholar
• . Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50(3):433–440
   PubMed Web of Science ®Google Scholar
• . Crowther MA, Clase CM, Margetts PJ, . Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002;13(9):2331–2337
   Google Scholar
• . Wilkieson TJ, Ingram AJ, Crowther MA, . Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol. 2011;6(5):1018–1024
   Google Scholar
• . Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315–328
   PubMed Web of Science ®Google Scholar
• . Cook D, Heyland D, Griffith L, Cook RMarshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27(12):2812–2817
   Google Scholar
• . Kaplan RC, Heckbert SR, Psaty BM. Risk factors for hospitalized upper or lower gastrointestinal tract bleeding in treated hypertensives. Prev Med. 2002;34(4):455–462
   Google Scholar
• . Wasse H, Gillen DL, Ball AM, . Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int. 2003;64(4):1455–1461
   PubMed Web of Science ®Google Scholar
• . Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223–2233
   PubMed Web of Science ®Google Scholar
• . Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662–2668
   PubMed Web of Science ®Google Scholar
• . Limdi NA, Limdi MA, Cavallari L, . Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56(5):823–831
   PubMed Web of Science ®Google Scholar
• . Dreisbach AW, Japa S, Gebrekal AB, . Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73(5):475–477
   Google Scholar
• . Holden RM, Iliescu E, Morton AR, Booth SL. Vitamin K status of Canadian peritoneal dialysis patients. Perit Dial Int. 2008;28(4):415–418
   Google Scholar
• . Cranenburg EC, Schurgers LJ, Uiterwijk HH, . Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82(5):605–610
   PubMed Web of Science ®Google Scholar
• . Westenfeld R, Krueger T, Schlieper G, . Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59(2):186–195
   PubMed Web of Science ®Google Scholar
• . Limdi NA, Beasley TM, Baird MF, . Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20(4):912–921
   PubMed Web of Science ®Google Scholar
• . Goodman WG, Goldin J, Kuizon BD, . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483
   PubMed Web of Science ®Google Scholar
• . Ketteler M, Rothe H, Kruger T, Biggar PH, Schlieper G. Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol. 2011;7(9):509–516
   PubMed Web of Science ®Google Scholar
• . Kavousi M, Elias—Smale S, Rutten JH, . Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–444
   PubMed Web of Science ®Google Scholar
• . Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3(5):1504–1510
   PubMed Web of Science ®Google Scholar
• . Koos R, Mahnken AH, Muhlenbruch G, . Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96(6):747–749
   Google Scholar
• . Weijs B, Blaauw Y, Rennenberg RJ, . Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011;32(20):2555–2562
   PubMed Web of Science ®Google Scholar
• . Villines TC, O'Malley PG, Feuerstein IM, Thomas S, Taylor AJ. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study. Calcif Tissue Int. 2009;85(6):494–500
   Google Scholar
• . Shea MK, O'Donnell CJ, Hoffmann U, . Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009;89(6):1799–1807
   Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROS Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Fox KA, Piccini JP, Wojdyla D, . Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394
   PubMed Web of Science ®Google Scholar
• . Liesenfeld KH, Lehr T, Dansirikul C, . Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–2175
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523–1532
   PubMed Web of Science ®Google Scholar
• . Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649–2661
   PubMed Web of Science ®Google Scholar
• . Sobieraj—Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009;35(5):515–524
   Google Scholar
• . www.ClinicalTrials.gov. An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients. NCT01590823. Accessed August 15, 2012
   Google Scholar
• . Herzog CA, Asinger RW, Berger AK, . Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–586
   PubMed Web of Science ®Google Scholar
• . Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–544
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Herzog CA, Asinger RW, Berger AK, . Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–586
   PubMed Web of Science ®Google Scholar
• . Phelan PJ, O'Kelly P, Holian J, . Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol. 2011;75(3):204–211
   Google Scholar
• . To AC, Yehia M, Collins JF. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrology. 2007;12(5):441–447
   Google Scholar